Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase InhibitorHiroaki Akamatsu, Nobuyuki Yamamoto, Motoko Tachihara et al.|JAMA Oncology|2021Cited by 185
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Kazushige Wakuda et al.|Journal of Thoracic Oncology|2022Cited by 158